COST-EFFECTIVENESS IN ENGLAND OF CABOZANTINIB FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (ARCC) AFTER FAILURE OF PRIOR THERAPY

被引：2
|
作者：
Lister, J. [1 ]
Vataire, A. [2 ]
Amzal, B. [3 ]
Dinet, J. [2 ]
Meng, J. [1 ]
Karcher, H. [3 ]
Gabriel, S. [2 ]
机构：
[1] Analytica LASER, Lorrach, Germany
[2] Ipsen Pharma, Boulogne, France
[3] Analytica Laser, London, England
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.245
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN162
引用
下载
收藏
页码：A441 / A441
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF CABOZANTINIB FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AFTER FAILURE OF PRIOR THERAPY IN BRAZIL
    Serafini, P.
    Stefani, S.
    Nebel de Mello, A.
    VALUE IN HEALTH, 2019, 22 : S67 - S67
  • [2] THE COMPARATIVE COST-EFFECTIVENESS OF CABOZANTINIB, EVEROLIMUS AND AXITINIB IN ADVANCED RENAL CELL CARCINOMA (ARCC) AFTER FAILURE OF PRIOR THERAPY: SCOTTISH PERSPECTIVE
    Lister, J.
    Vataire, A.
    Amzal, B.
    Dinet, J.
    Meng, J.
    Karcher, H.
    Gabriel, S.
    VALUE IN HEALTH, 2017, 20 (09) : A440 - A440
  • [3] COST-EFFECTIVENESS OF CABOZANTINIB FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AFTER FAILURE OF PRIOR THERAPY IN SOUTH KOREA
    Kim, S.
    Han, S.
    Kim, H.
    Suh, H. S.
    VALUE IN HEALTH, 2018, 21 : S39 - S39
  • [4] Cost-Effectiveness and Value of Information of Cabozantinib Treatment for Patients with Advanced Renal Cell Carcinoma After Failure of Prior Therapy in South Korea
    Siin Kim
    Sola Han
    Hyungtae Kim
    Hae Sun Suh
    Applied Health Economics and Health Policy, 2021, 19 : 545 - 555
  • [5] Cost-Effectiveness and Value of Information of Cabozantinib Treatment for Patients with Advanced Renal Cell Carcinoma After Failure of Prior Therapy in South Korea
    Kim, Siin
    Han, Sola
    Kim, Hyungtae
    Suh, Hae Sun
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2021, 19 (04) : 545 - 555
  • [6] Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England
    Meng, Jie
    Lister, Johanna
    Vataire, Anne-Lise
    Casciano, Roman
    Dinet, Jerome
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 243 - 250
  • [7] Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis
    Shlomai, Amir
    Leshno, Moshe
    Goldstein, Daniel A.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2019, 12
  • [8] Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma in Sweden
    Johal, S.
    Johannesen, K. M.
    Malcolm, B.
    Doan, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma
    Liu, Ruizhe
    Qiu, Kaifeng
    Wu, Junyan
    Jiang, Yanqing
    Wu, Peihao
    Pang, Jianxin
    IMMUNOTHERAPY, 2022, 14 (11) : 859 - 869
  • [10] COST-EFFECTIVENESS OF CABOZANTINIB VERSUS SUNITINIB OR PAZOPANIB AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN THE UK
    Skentzou, E.
    Meng, J.
    Lister, J.
    Gray, L.
    VALUE IN HEALTH, 2018, 21 : S30 - S30
12345